Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Average PT from Analysts

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) have earned an average recommendation of "Buy" from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock in the last year is $10.33.

Several analysts recently weighed in on the stock. Bank of America cut their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Caribou Biosciences in a research note on Wednesday, March 19th.

Hedge Funds Weigh In On Caribou Biosciences

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company's stock valued at $3,980,000 after buying an additional 124,782 shares during the last quarter. Sei Investments Co. purchased a new stake in Caribou Biosciences in the 4th quarter worth about $102,000. US Bancorp DE lifted its stake in Caribou Biosciences by 3,524.2% in the fourth quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after purchasing an additional 26,467 shares during the last quarter. Barclays PLC boosted its position in shares of Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company's stock valued at $255,000 after buying an additional 71,463 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Caribou Biosciences by 475.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after buying an additional 2,062,563 shares during the last quarter. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Up 5.1 %

Shares of Caribou Biosciences stock traded up $0.04 during trading on Thursday, reaching $0.84. 915,799 shares of the stock were exchanged, compared to its average volume of 1,561,020. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $4.21. The firm has a market cap of $77.72 million, a price-to-earnings ratio of -0.51 and a beta of 2.36. The stock's fifty day moving average is $1.01 and its 200 day moving average is $1.56.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.08 million during the quarter, compared to analysts' expectations of $2.11 million. Equities analysts forecast that Caribou Biosciences will post -1.64 earnings per share for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.